Latest News｜Institute for Biotechnology and Medicine Industry│IBMI

Latest News

Date	Subject	Media
2022-03-03	Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and Other Derivative Products	Press Release
2022-03-03	NCCN Clinical Practice Guidelines in Oncology Update Recommends BESREMi® for the Treatment of Polycythemia Vera	Press Release
2022-03-02	Lotus obtained marketing authorizations for Lenalidomide and Gefitinib in Philippines	Press Release
2022-02-24	Japan order first from overseas for ITRI test kit	Taipei Times
2022-02-24	Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement	Press Release
2022-02-23	OBI Pharma Enters License Agreement with Odeon Therapeutics for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau	Press Release
2022-02-22	The data of SNS812, an anti-Pan-COVID19 siRNA, co-developed by Oneness & MBS and supervised by NTU professors, were published today by EMBO Mol. Medicine	Press Release
2022-02-21	Taiwan's NHRI: Survival length of biliary tract cancer patients dramatically prolonged in study of new chemotherapy regimen	Press Release
2022-02-16	Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries	Press Release
2022-02-16	Taiwan unveils potential mRNA vaccine for all COVID variants including Omicron	Taiwan News

■ Most Watched

■ Industry Watch

■ IBMI News

Information appearing on this website (images and texts, unless otherwise indicated) is the property of IBMI. To use or share, please indicate the source.

Address：9F., No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist., Taipei City , Taiwan (R.O.C.) Contact Number：(02)2655-8168 Fax：(02)2655-7978